Trastuzumab emtansine
Kadcyla (trastuzumab emtansine) is an antibody pharmaceutical. Trastuzumab emtansine was first approved as Kadcyla on 2013-11-15. It has been approved in Europe to treat breast neoplasms.
| Trade Name | Kadcyla |
|---|---|
| Common Name | Trastuzumab emtansine |
| Indication | breast neoplasms |
| Drug Class | Monoclonal antibodies: humanized, tumors as target; maytansinoid derivatives |
